Roche Holding AG hired a senior executive from rival Novo Nordisk A/S as the Swiss drugmaker prepares to enter the hyper-competitive market for obesity drugs.
Morten Lammert will join Roche as its global therapeutic area head for cardiovascular, renal and metabolism on June 1, a spokesman for the company said. The role, which focuses on the commercial market rather than on research and development, did not previously exist at Roche.